Migraine With Aura

Earn CME/CE in your profession:

Continuing Education Activity

Migraine is one of the most common headache disorders affecting approximately 12% of the general population. A timely diagnosis is essential to avoid debilitating consequences. Migraine auras are the sensory symptoms (neurologic, gastrointestinal, and autonomic) that can occur before or during a migraine episode. These symptoms can include flashes of light, blind spots, or tingling in the hands or face. This activity describes various types, pathophysiology, evaluation, and treatment of migraine headaches with aura and highlights the role of the healthcare team in evaluating and managing patients with this condition.


  • Identify the etiology of migraine headache with aura.
  • Review the appropriate evaluation of migraine headache with aura.
  • Outline the management options available for migraine headaches with aura.
  • Describe interprofessional team strategies for improving care coordination and communication to identify migraine headaches with aura and improve outcomes.


Migraine is one of the common types of headache disorder that can present with a wide variety of symptoms. The word migraine derives from the Latin word ‘hemicrania,’ meaning ‘half skull.’ The term ‘migraine’ was first used by the Greek physician, Galenus of Pergamon. Migraine auras are the sensory symptoms (neurologic, gastrointestinal, and autonomic) that can occur before or during a migraine episode. These symptoms can include flashes of light, blind spots, or tingling in the hands or face. Migraine without aura accounts for 70% of patients with migraine headaches.


The exact etiology of various aspects of migraine is not completely understood. It is believed that a primary neuronal dysfunction leads to a sequence of changes intracranially and extracranially, which causes migraines. The aura of migraine is thought to be due to neuronal and glial depolarization that spreads across the cerebral cortex.[1] This, in turn, activates trigeminal afferents, which cause inflammatory changes in the pain-sensitive meninges that generate the migraine headache through central and peripheral reflex mechanisms.

Genetics and Inheritance

Migraine has a strong genetic component. The risk of migraines in ill relatives is three times greater than that of relatives of non-ill subjects, but no inheritance pattern was identified. The genetic basis of migraine is complex, and it is uncertain which loci and genes are the ones implicated in the pathogenesis; it may be based on more than one genetic source at different genomic locations acting in tandem with environmental factors to bring susceptibility and the characteristics of the disease in such individuals.[2][3] Identifying these genes in an individual with migraines could predict the targeted prophylactic treatment.


Withdrawn or exposure to several factors contribute to the development of migraine headaches. A retrospective study found that 76% of the patients reported triggers.[4] Some of the precipitating factors for migraine headaches include:

  • Certain food items like aged cheese, food additives like nitrates (as used in hot dogs), and monosodium glutamate (MSG) can be responsible in a few patients.
  • High-stress levels and anxiety
  • Caffeine: High intake of coffee or withdrawal from coffee can precipitate migraines.
  • Weather changes: Storm fronts, strong winds, or changes in altitude can sometimes trigger a migraine.
  • Sleep disturbances: Lack of adequate sleep or too much sleep can trigger a migraine.
  • Menstrual period: Many women can have migraine episodes during their menstrual periods and be symptom-free otherwise.
  • Exposure to bright lights, loud noise, or strong odors[5]


Migraine affects about 12% of the general population. Women are affected more compared to men. The prevalence of migraines is two to three times in women compared to men.[6] Migraine tends to run in families. It is consistently the fourth or fifth most common reason for emergency visits accounting for an annual 3% of all emergency visits.[7] Its prevalence increases in puberty but continues to increase until 35 to 39 years of age, decreasing later in life, especially after menopause.[8] Moreover, it is considered the second major cause of disability after back pain with respect to years of life lived with disability.


Multiple mechanisms are believed to be involved in the pathophysiology of migraines. 

Cortical Spreading Depression

Neuronal and glial depolarization spreading across the cerebral cortex is thought to cause the aura of the migraine.[1] This activates the trigeminal afferents, which cause inflammatory changes in the meninges, leading to pain. 

Trigeminovascular System

Activation of the trigeminovascular system is also believed to be involved in the pathophysiology of migraine. The trigeminovascular system consists of sensory neurons originating from the trigeminal ganglion and upper cervical dorsal roots: these sensory neurons project to innervate large cerebral vessels, dura mater, and dial vessels. The convergence of these projections at the trigeminal nucleus caudalis explains the distribution of migraine pain that involves anterior and posterior regions of the head and the upper neck. Trigeminal ganglion stimulation leads to the release of vasoactive neuropeptides like substance P, neurokinin A, and calcitonin-gene-related peptide (CGRP), which in turn leads to neurogenic inflammation.[9]

Role of Serotonin

Serotonin, released from the brainstem serotonergic nuclei, may play a role in migraine; however, the exact role of its mechanisms remains a matter of controversy.[10] Most likely, serotonin levels are low between attacks because it may cause a deficiency in the serotonin pain inhibition system, therefore helping the activation of the trigeminal system. It could mediate by acting directly over the cranial vessels or in central pain control pathways, or by cortical projections of brainstem serotonergic nuclei.[11][12] Serotonin is thought to be involved in the pathogenesis of migraines due to its direct action on the cranial vasculature and its role in central pain control pathways. 

Role of CGRP

Calcitonin gene-related peptide (CGRP) plays an essential role in the pathogenesis of migraines. CGRP is a neuropeptide that has a vasodilatory effect on the cerebral and the dural vessels.[13][14] It mediates pain transmission to the central nervous system from the intracranial vessels. It is also involved in the vasodilatory component of neurogenic inflammation.[15]


The process of neurons becoming increasingly sensitive to nociceptive and non-nociceptive stimulation is called sensitization. Sensitization in primary afferent neurons, the second-order neurons in the trigeminal nucleus caudalis, and higher-order neurons in the central nervous system play a role in migraine attacks. Sensitization also explains the throbbing quality of migraine pain, hyperalgesia, and worsening pain with coughing and sudden head movements.

Genetic Basis

The genetic basis of migraines is complex. Some migraine disorders are believed to be caused due to mutations in a single gene, while others are caused due to polymorphisms in many genes.[16] Mutations in three different ion channel genes, CACNA1A, SCN1A, and ATP1A2, are found to be causal in migraine disorders in family studies. Also, hemiplegic migraine (migraine with motor weakness) is believed to be dominantly inherited.[17]

History and Physical

Migraine is a disorder that usually occurs as recurrent attacks. A migraine attack can last from hours to days. A typical migraine attack passes through 4 phases: the prodromal phase, the aura phase, the headache phase, and the postdromal phase.

Prodromal Phase

This involves symptoms usually occurring 24 to 48 hours before the headache onset. Some of the common prodromal symptoms are irritability, depression, increased yawning, neck stiffness, and craving for specific foods.

Aura Phase

Aura is seen in about 25% of patients with migraines. Aura can precede the headache, or sometimes headaches start along with aura. A typical aura can present with positive or negative symptoms and is completely reversible.[2] Active discharge from the central nervous system neurons leads to positive symptoms. Absence or loss of function leads to negative symptoms. 

Aura can be visual, auditory, somatosensory, or motor. Visual aura can be a flickering, jagged arc of light, bright lines, or a blind spot in the visual field.[18] An auditory aura may be in the form of tinnitus, music, or noises. Sensory aura can present as tingling, numbness, or paresthesias. Language aura is rare and can present as word-finding difficulty or trouble understanding words. Motor aura can present as a weakness of one side of the face or one side of the body. This very rare form is classified as a "hemiplegic migraine."

Some patients experience isolated aura without the development of migraine headaches. This is called 'migraine equivalent' or 'acephalgic migraine.' 

Headache Phase

A migraine headache can be unilateral or bilateral. The pain is usually described as throbbing or pulsatile. Headaches can be accompanied by nausea or vomiting. Intensity can vary from moderate to severe. Many patients report phonophobia or photophobia during the attacks. They get relief from sleeping in a dark, quiet room. 

Postdromal Phase

In this phase, patients can report transient headaches on sudden head movements. Patients can also experience extreme tiredness and exhaustion.


Migraine is a clinical diagnosis. A good history and physical examination are necessary to diagnose.

The necessary information that has to be gathered consists of these simple questions:

  • Demographic features of the patient: age, gender, race, profession
  • When did the headache start?
  • Where does it hurt? Location, irradiation.
  • What is the intensity of the pain?
  • How is the pain? Which are the qualitative characteristics of pain?
  • How long does the pain last?
  • In which part of the day does the pain appear?
  • How has it evolved since it started?
  • What is the frequency of appearance?
  • What are the triggering situations?
  • Simultaneous symptoms?
  • Is it related to sleep?
  • How does it get better or worse?
  • Which medications do you take to make it better? What is the frequency of this medication?

Following are certain criteria specified by the International Classification of Headache Disorders, 3rd edition (ICHD-3), which can help in diagnosing migraine with aura:

  • A. At least two attacks that fulfill criteria B and C
  • B. One or more of the following aura symptoms that are reversible:
    • Visual, retinal, sensory, brainstem, motor, speech, or language
  • C. At least three of the six characteristics below:
    • At least one aura symptom that spreads gradually over greater than 5 minutes
    • Two or more symptoms in succession
    • At least one unilateral aura symptom
    • At least one positive aura symptom
    • Each aura symptom lasts 5 to 60 minutes
    • Aura accompanied by or followed by headache within 60 minutes[18]
  • D. No other ICHD-3 diagnosis accounting for the symptoms

Patients should also be inquired about somatosensory disturbances, such as spreading unilateral numbness or tingling in the face and arm, as well as about disturbances in speech or thinking. Some aura symptoms, as described below, could indicate uncommon types of migraine:

  • Motor weakness
  • Dysarthria
  • Hypacusis
  • Diplopia
  • Ataxia
  • Vertigo
  • Tinnitus
  • Decreased level of consciousness

There is no diagnostic test for migraines. Hence, most patients do not need any neuroimaging. Neuroimaging may be indicated in the following situations:

  • Sudden onset of severe headache
  • New neurological symptom or sign-on examination
  • Headache not responding to treatment
  • Headache lasting > 72 hours
  • New-onset headaches in patients greater than 50 years of age
  • A significant change in the frequency, pattern, or severity of headaches
  • Severe headache pain ("worst headache of life") or headache causing awakening from sleep
  • New-onset headache in patients with HIV infection or cancer
  • Associated symptoms or signs suggestive of meningitis or stroke[19]

Treatment / Management

Migraine treatment involves abortive and prophylactic therapy. Abortive treatment is to stop a headache that has already started from progressing further. Prophylactic therapy aims to reduce the frequency or severity of headaches, thereby improving patients' quality of life.

Abortive Therapy

  • Acute treatment aims to stop the progression of a headache. It has to be treated quickly and with a large single dose. Oral agents can be ineffective in patients with migraine-induced gastric stasis. Therefore, parenteral medication could be the rule for some patients, especially those with nausea or vomiting.[20][21][22] Therapy consists of stratified options:
    • NSAIDs (nonsteroidal anti-inflammatory drugs): ibuprofen (400 to 600 mg), naproxen (275 to 825 mg), diclofenac (65 mg), aspirin (900 to 1000 mg), or acetaminophen (1000 mg).[23] Usually, in mild to moderate attacks without nausea or vomiting. If one NSAID is ineffective, another class of drug should be used.
    • Triptans (the first line in patients with allodynia): sumatriptan (administered as a subcutaneous injection of 6 mg, a nasal spray of 20 to 40 mg over 24 hours, a nasal powder of 10 to 30 mg over 24 hours, or orally 50 to 100 mg once), zolmitriptan 10 mg per 24 hours (nasal 2.5 to 5 mg as a single dose and oral 2.5 mg as a single dose), eletriptan, rizatriptan, almotriptan. With or without naproxen for moderate to severe attacks. Unlike NSAIDs, patients who do not respond well to one triptan may respond to another; therefore, therapy may be individualized.
      • To avoid medication overuse, triptans should be limited to less than ten days of use within a month.
      • Because of the activation of the 5-HT(1B) and 5-HT(1D) receptors on coronary arteries and cerebral vessels, there are recommendations against its use in patients with ischemic stroke, ischemic heart disease, poor-controlled hypertension, angina, pregnancy, hemiplegic or basilar migraine. In these patients with cardiovascular risks, the best-suited medication is a selective serotonin 1F receptor agonist that does not produce vasoconstriction; lasmiditan.
      • It is recommended to monitor therapy if the patient takes selective serotonin reuptake inhibitors or selective serotonin-noradrenaline reuptake inhibitors because of the risk of serotonin syndrome.
      • The combination of nonsteroidal anti-inflammatory drugs (NSAID) with triptan appears more effective than using either drug class alone. Sumatriptan succinate 85 mg and naproxen sodium 500 mg in a single tablet may be prescribed as initial therapy.[24]
      • The use of triptans should be limited to no more than ten days of use per month to avoid medication overuse headaches.
    • Antiemetics: metoclopramide, chlorpromazine, prochlorperazine. They are generally used as adjunctive therapy with NSAIDs or triptans to decrease nausea and vomiting, especially in the emergency department. Diphenhydramine can also be added to prevent dystonic reactions (mostly with metoclopramide).
    • Calcitonin-gene-related peptide antagonists: These include rimegepant (75 mg as a single dose) and ubrogepant. It could be considered in patients who don't respond to conventional treatment or those with coronary artery disease.[25] The use of rimegepant for both migraine treatment and prevention concurrently has not been studied.
    • Selective serotonin 1F receptor agonist: US Food and Drug Administration (FDA) approved lasmiditan oral tablets in October 2019 for the acute treatment of migraine in adults. The initial dose of lasmiditan is 50 or 100 mg, particularly effective for patients who cannot use triptans due to cardiovascular risks. The dose may be increased to 100 or 200 mg per requirement, but no more than one dose should be taken over 24 hours. However, one significant side effect is dizziness. So patients should not engage in potentially hazardous activities or drive a motor vehicle for at least eight hours after each dose of lasmiditan. Some other adverse effects are nausea, fatigue, and paresthesia.[26]
    • Ergots: ergotamine and dihydroergotamine (intravenous (IV), intramuscular (IM), subcutaneous, and intranasal use), recommended for acute attacks as a parenteral administration and effective as bridge therapy for medication overuse headache and status migrainosus. Ergotamine has not demonstrated particular effectiveness yet, and it can present significant side effects, including cerebrovascular, cardiovascular, and peripheral ischemic complications.
    • Dexamethasone can reduce the recurrence of early headaches but does not provide immediate relief of headaches.[27][28]
    • Transcutaneous supraorbital nerve stimulation can reduce intensity.[29]
    • Transcranial magnetic stimulation is proved effective as a second-line treatment, with no serious side effects. It can also be offered as an option to treat chronic migraines. It is contraindicated in patients with epilepsy.[30][31]
    • Nonpainful remote electric neurostimulation could be considered a first-line treatment in some patients.[32]
    • Peripheral nerve blocking (occipital plexus and sphenopalatine ganglion).[33][34]

Migraine Treatment in the Emergency Setting

Patients presenting to an emergency room with severe migraine headaches associated with nausea and vomiting can be managed with:

  •  Sumatriptan
  •  Antiemetics/dopamine receptor blockers like metoclopramide, prochlorperazine, or chlorpromazine
  •  Dihydroergotamine with metoclopramide
  •  Ketorolac

It is recommended to add dexamethasone in patients treated with the above therapies to reduce the risk of early headache recurrence. 

Prophylactic Therapy

  • Prophylactic therapy is indicated in patients with frequent or long-lasting migraine headaches, headaches causing significant disability and affecting the quality of life, or when acute therapies are contraindicated.[35]
  • The drugs for prophylactic therapy are usually started at a low dose and gradually titrated up until the patient gets the therapeutic benefit.
  • Some of the agents used in prophylactic therapy are:[36]
    • Beta-blockers like metoprolol or propranolol
    • Antidepressants like amitriptyline or venlafaxine
    • Anticonvulsants like valproate or topiramate
    • Calcium channel blockers like verapamil or flunarizine

Certain noninvasive neuromodulatory approaches, such as supraorbital or vagal nerve stimulation, are emerging as a part of prophylactic methods for migraines.[37] Injection of botulinum neurotoxin A (BoNT-A) is also effective in chronic refractory migraines.[38]

Lifestyle Measures

Lifestyle measures to control migraine headaches include routine meal schedules, regular exercise, good sleep hygiene, and managing migraine triggers.

Differential Diagnosis

Tension-type Headache

Tension-type headache is usually bilateral, compared to migraine headaches, which are unilateral in about 60% to 70% of adults. Tension headache feels like pressure or tightness around the head, which waxes and wanes. It is not commonly accompanied by photophobia, photophobia, nausea, or vomiting.

Cluster Headache

Cluster headache is usually unilateral, and the pain begins around the eye. The pain is severe and reaches a crescendo within minutes, unlike a migraine headache, where the pain is gradual in onset. Associated symptoms in cluster headaches include ipsilateral redness and lacrimation of the eye, rhinorrhea, stuffy nose, and sweating, and responding well to oxygen therapy. 

Transient Ischemic Attack (TIA)

The differential diagnosis for migraine with aura includes TIA. The symptoms are sudden in onset in a TIA, whereas in a migraine, the symptoms are relatively gradual in onset. Also, positive aura symptoms like visual scintillations or paresthesias and associated symptoms of photophobia, phonophobia, nausea, and vomiting are less likely in a TIA.

Treatment Planning

Drug Class/Drug Drug Dose Range Notes
Nonsteroidal anti-inflammatory drugs[39]
  • Aspirin[23]
  • Ibuprofen
  • Naproxen
  • Diclofenac
  • Diclofenac epolamine
  • Tolfemanic acid
  • Celecoxib[40]
  • Dexletoprofen
  • 900-100 mg
  • 400-600 mg
  • 275-825 mg
  • 50-100 mg
  • 65 mg
  • 200 mg
  • 120 mg
  • 50 mg
All NSAIDs have similar efficacy 
Non-opioid analgesic
  • 1000-3000 g
Acute-life threatening hepatotoxicity at > 4 g/d

Serotonin 1b/1d agonists (triptans)


  • Sumatriptan (oral)




  • Sumatriptan (intranasal solution)




  • Sumatriptan (intranasal powder)




  • Sumatriptan (spray)




  • Sumatriptan (subcutaneous)
  • 50-100 mg as a single dose, maximum dose: 200 mg/d[42]


  • 20 mg as a single dose in 1 nostril; if symptoms persist, may repeat dose after ≥2 hours, maximum dose: 40 mg/d


  • 22 mg as a single dose, may repeat dose after ≥2 hours if symptoms persist or return, maximum dose: 44 mg/d


  • 10 mg as a single dose in 1 nostril. Repeat dose after ≥1 hour if symptoms persist or return; maximum dose: 30 mg/d


  • 6 mg as a single dose, may repeat dose (usually same as the first dose) after ≥1 hour if symptoms persist or return, or lesser dosage if 6 mg was not tolerated, maximum dose: 6 mg/dose; 12 mg/d[43]

All formulations of triptans are contraindicated in severe hepatic impairment.

Contraindicated in patients with cardiovascular illness as prolonged QT interval on ECG and subsequent ventricular arrhythmias, including torsades de pointes (TdP) and ventricular fibrillation, are reported.

May also cause dizziness, lethargy, tremor, vertigo, akathisia, dystonia, and pathological laughter.

Other vasospasm-related events include peripheral ischemia, ischemic colitis, splenic infarction, and Raynaud disease.

Should be avoided in patients with uncontrolled hypertension and pregnancy.

Ocular side effects like transient and permanent blindness and significant partial vision loss

The use of concomitant serotonergic drugs may cause serotonin syndrome.

Unpleasant taste is lower with intranasal zolmitriptan as compared to intranasal sumatriptan.

Patients who do not respond to one triptan may respond to another.

Naratriptan and frovatriptan have a slower onset and lower efficacy.

Serotonin 1b/1d agonists (triptans)


  • 2.5 mg as a single dose; may repeat dose after ≥4 hours; maximum dose: 2.5 mg/dose; 5 mg/d.

Use within 24 hours of an ergotamine preparation or a different triptan is not advised.

Contraindicated with severe renal impairment (CrCl <15 mL/minute).

Serotonin 1b/1d agonists (triptans)


  •  Zolmitriptan (oral)



  • Zolmitriptan (intranasal)
  •  2.5 mg as a single dose; may repeat dose after ≥2 hours; maximum dose: 5 mg/dose; 10 mg/d


  • 2.5 to 5 mg as a single dose; may repeat dose after ≥2 hours; maximum: 5 mg/dose; 10 mg/d
Refer to the section on sumatriptan above for the side effects of triptans.

Serotonin 1b/1d agonists (triptans)


  • Frovatriptan 
  • 2.5 mg as a single dose; may repeat dose after ≥2 hours if needed; maximum dose: 2.5 mg/dose; 5 mg/d  
Slower onset 

Serotonin 1b/1d agonists (triptans)


  • Almotriptan 
  • 12.5 mg as a single dose; may repeat dose after ≥2 hours when needed; maximum dose: 12.5 mg/dose; 25 mg/d 
Reduce dose to half with hepatic impairment 

Serotonin 1b/1d agonists (triptans)



  • 5 to 10 mg as a single dose; may repeat dose after ≥2 hours if needed; maximum dose: 20-30 mg/d
Propranolol increases rizatriptan levels by 70%. So the dose of rizatriptan must be adjusted downward in these patients.

Serotonin 1b/1d agonists (triptans)


  • Eletriptan
  • 40 mg as a single dose; may repeat dose after ≥2 hours if needed; maximum dose: 40 mg/dose; 80 mg/d[47]
Primarily metabolized by cytochrome P-450 enzyme CYP3A4. Not advised within at least 72 hours of treatment with other drugs that are potent CYP3A4 inhibitors: itraconazole, ketoconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, and nelfinavir.


  • Metoclopramide (IV, IM, oral)[48]


  • Prochlorperazine (IV, IM)
  • 10-20 mg as a single dose


  • 10 mg as a single dose
IV route is preferred for metoclopramide. Pretreat with diphenhydramine to prevent akathisia and other acute dystonic reactions.
Calcitonin-gene-related peptide (CGRP) antagonists



  • 75 mg every other day; maximum dose: 75 mg/d


  • 50 to 100 mg as a single dose; may repeat dose after ≥2 hours if needed; maximum dose: 200 mg/d

Administration early in the course of a migraine attack may improve response to treatment.

Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.

More studies are needed to establish efficacy and safety.

 Serotonin 5-HT1F receptor agonist
  • Lasmiditan
  • 50 to 100 mg as a single dose; may increase to 100 or 200 mg as a single dose if needed; repeat doses have not established efficacy.[50]

Administration early in the course of a migraine attack may improve response to treatment.

Second-line therapy when triptans are contraindicated, poorly tolerated, or ineffective.

A significant side effect is dizziness (9% to 17%). Wait for at least 8 hours between dosing and driving or operating heavy machinery.

May enhance the CNS depressant effect of alcohol.

 Ergot derivative[51]
  •  Dihydroergotamine
  • IM: 1 mg as a single dose; may repeat hourly as required; maximum dose: 3 mg/d, 6 mg/week
  • IV: 1 mg as a single dose; may repeat hourly as required; maximum dose: 2 mg/d, 6 mg/week
  • SUBQUT: 1 mg as a single dose; may repeat 2 hourly as required; maximum dose: 3 mg/d, 6 mg/week
  • Intranasal: 0.5 mg per spray: 1 spray (0.5 mg) into each nostril; repeat after 15 minutes (total of 4 sprays per dose); maximum dose: 4 sprays (1 dose)/d


Use is contraindicated in severe hepatic or renal impairment as well as pregnancy or breastfeeding.

Also contraindicated in patients with hypertension or ischemic heart disease.

Should not be used within 24 hours of triptans or ergot-like agents.

Use with potent inhibitors of CYP3A4 (including azole antifungals, protease inhibitors, and some macrolide antibiotics) is also avoided.

Table 1. Acute therapy for migraine

*Adverse effects in this section pertain to all the triptans unless specified

Drug Class Drug Dose Range Adverse Effects/Contraindications
Beta-adrenoceptor blockers[52]
  • Propranolol
  • Metoprolol
  • Timolol
  • 80-240 mg
  • 50-150 mg
  • 10-20 mg
  • Contraindicated in asthma, syncope, heart block
  • Amitriptyline
  • Nortriptyline
  • Venlafaxine
  • 10-150 mg
  • 25-100 mg
  • 37.5-150 mg
  • Somnolence
  • Insomnia, hypertension
Calcium-channel blockers
  • Verapamil
  • 180-480 mg
  • Constipation, hypotension, edema
Antiepileptic drugs
  • Divalproex sodium
  • Topiramate
  • Gabapentin
  • 200-1500 mg
  • 25-150 mg
  • 300-1800 mg
  • Weight gain, thrombocytopenia, tremor
  • Renal calculi, amnesia, glaucoma, dysequilibrium, weight loss
CGRP monoclonal antibodies
  • Erenumab[53]
  • Galcanezumab
  • 70-140 mg every 4 weeks, subcutaneously
  • 120 mg monthly subcut
  • Injection site reactions, muscle spasms, hypersensitivity reaction.
  • Injection site reactions, vertigo, pruritus, constipation

Table 2. Preventive therapy for migraine


Migraine is a fairly benign disorder, though it can affect the quality of life in some patients. With increasing age, the frequency and severity of migraine headaches tend to diminish. Though migraine is a chronic disorder, prolonged remissions are common. Menstrual migraine tends to get better after menopause in terms of the severity of symptoms and frequency of headaches. Patients who follow lifestyle changes, including meal schedules and good sleep hygiene, have a good prognosis.


Status Migrainosus

This is a debilitating migraine attack that tends to last for more than 72 hours. Some patients with status migrainosus require hospitalization due to intense pain.

Migrainous Infarction or Stroke

Patients with migraine with aura have a higher risk of stroke. Migrainous infarction is a migraine attack in patients with aura, wherein the aura symptoms last for more than an hour, and infarction is seen on the neuroimaging. 

Persistent Aura without Infarction

This can be seen in patients where the aura lasts for more than a week after the migraine headache has ended. Patients can have symptoms similar to migrainous infarction, but neuroimaging does not show any infarction.

Migraine-aura Triggered Seizure

This is a seizure triggered by a migraine attack with aura. The seizure typically occurs within an hour after a migraine attack.

Mental Health Issues

Some patients with migraine headaches are at an increased risk of having a major depressive disorder, bipolar disorder, or posttraumatic stress disorder.

Deterrence and Patient Education

Timely diagnosis and management of migraine headaches are essential, as they can sometimes be debilitating and affect the quality of life. Patients should be educated about the different phases of migraine headaches and the benefits of abortive and prevention therapy. Patients should be educated about lifestyle changes, which can help in reducing the frequency and severity of migraine attacks. Patients should also be instructed to go to a doctor in case of worsening symptoms or the occurrence of new neurological symptoms, which might warrant neuroimaging.

Enhancing Healthcare Team Outcomes

As migraine headache is a clinical diagnosis, providers need to be aware of various presentations of migraine, to reduce unnecessary investigations and neuroimaging. Optimal management will require the efforts of an interprofessional healthcare team. A good history and physical examination can rule out other differentials and help diagnose migraine. An interprofessional approach is necessary for the management of patients with migraines. Neurologists should be involved in patient care when a primary care provider is unsure of the diagnosis. With proper management, most patients with migraine headaches have a good prognosis. Neuroscience and pain control nurses can work with patients on lifestyle changes and educate them about the use of medications. Pharmacists must review prescriptions, consult with the prescriber on optimal agent selection, check for drug-drug interactions, and inform patients about usage and side effects. Nurses can help monitor and reinforce medication teaching points and serve as a contact point connecting clinicians and other team members.

All team members must document all observations in the patient's medical record and reach out to the appropriate team members for necessary therapeutic interventions. These interprofessional efforts will help drive better outcomes for patients with migraine headaches. [Level 5]



12/6/2022 3:46:19 PM



Fraser CL, Hepschke JL, Jenkins B, Prasad S. Migraine Aura: Pathophysiology, Mimics, and Treatment Options. Seminars in neurology. 2019 Dec:39(6):739-748. doi: 10.1055/s-0039-1700525. Epub 2019 Dec 17     [PubMed PMID: 31847045]


. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia : an international journal of headache. 2018 Jan:38(1):1-211. doi: 10.1177/0333102417738202. Epub     [PubMed PMID: 29368949]


Merikangas KR, Risch NJ, Merikangas JR, Weissman MM, Kidd KK. Migraine and depression: association and familial transmission. Journal of psychiatric research. 1988:22(2):119-29     [PubMed PMID: 3404480]


Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia : an international journal of headache. 2007 May:27(5):394-402     [PubMed PMID: 17403039]


Marmura MJ. Triggers, Protectors, and Predictors in Episodic Migraine. Current pain and headache reports. 2018 Oct 5:22(12):81. doi: 10.1007/s11916-018-0734-0. Epub 2018 Oct 5     [PubMed PMID: 30291562]


Vetvik KG, MacGregor EA. Sex differences in the epidemiology, clinical features, and pathophysiology of migraine. The Lancet. Neurology. 2017 Jan:16(1):76-87. doi: 10.1016/S1474-4422(16)30293-9. Epub 2016 Nov 9     [PubMed PMID: 27836433]


Jen JC, Kim GW, Dudding KA, Baloh RW. No mutations in CACNA1A and ATP1A2 in probands with common types of migraine. Archives of neurology. 2004 Jun:61(6):926-8     [PubMed PMID: 15210532]


Ebrahimi-Fakhari D, Saffari A, Westenberger A, Klein C. The evolving spectrum of PRRT2-associated paroxysmal diseases. Brain : a journal of neurology. 2015 Dec:138(Pt 12):3476-95. doi: 10.1093/brain/awv317. Epub 2015 Nov 23     [PubMed PMID: 26598493]


Iyengar S, Johnson KW, Ossipov MH, Aurora SK. CGRP and the Trigeminal System in Migraine. Headache. 2019 May:59(5):659-681. doi: 10.1111/head.13529. Epub 2019 Apr 14     [PubMed PMID: 30982963]


Deen M, Christensen CE, Hougaard A, Hansen HD, Knudsen GM, Ashina M. Serotonergic mechanisms in the migraine brain - a systematic review. Cephalalgia : an international journal of headache. 2017 Mar:37(3):251-264. doi: 10.1177/0333102416640501. Epub 2016 Jul 11     [PubMed PMID: 27013238]

Level 1 (high-level) evidence


Suzuki M, Van Paesschen W, Stalmans I, Horita S, Yamada H, Bergmans BA, Legius E, Riant F, De Jonghe P, Li Y, Sekine T, Igarashi T, Fujimoto I, Mikoshiba K, Shimadzu M, Shiohara M, Braverman N, Al-Gazali L, Fujita T, Seki G. Defective membrane expression of the Na(+)-HCO(3)(-) cotransporter NBCe1 is associated with familial migraine. Proceedings of the National Academy of Sciences of the United States of America. 2010 Sep 7:107(36):15963-8. doi: 10.1073/pnas.1008705107. Epub 2010 Aug 23     [PubMed PMID: 20798035]


Lee HN, Eom S, Kim SH, Kang HC, Lee JS, Kim HD, Lee YM. Epilepsy Characteristics and Clinical Outcome in Patients With Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like Episodes (MELAS). Pediatric neurology. 2016 Nov:64():59-65. doi: 10.1016/j.pediatrneurol.2016.08.016. Epub 2016 Aug 26     [PubMed PMID: 27671241]

Level 2 (mid-level) evidence


Deen M, Correnti E, Kamm K, Kelderman T, Papetti L, Rubio-Beltrán E, Vigneri S, Edvinsson L, Maassen Van Den Brink A, European Headache Federation School of Advanced Studies (EHF-SAS). Blocking CGRP in migraine patients - a review of pros and cons. The journal of headache and pain. 2017 Sep 25:18(1):96. doi: 10.1186/s10194-017-0807-1. Epub 2017 Sep 25     [PubMed PMID: 28948500]


Yuan H, Lauritsen CG, Kaiser EA, Silberstein SD. CGRP Monoclonal Antibodies for Migraine: Rationale and Progress. BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2017 Dec:31(6):487-501. doi: 10.1007/s40259-017-0250-5. Epub     [PubMed PMID: 29116598]


Charles A, Pozo-Rosich P. Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet (London, England). 2019 Nov 9:394(10210):1765-1774. doi: 10.1016/S0140-6736(19)32504-8. Epub 2019 Oct 23     [PubMed PMID: 31668411]


Gasparini CF, Smith RA, Griffiths LR. Genetic and biochemical changes of the serotonergic system in migraine pathobiology. The journal of headache and pain. 2017 Dec:18(1):20. doi: 10.1186/s10194-016-0711-0. Epub 2017 Feb 13     [PubMed PMID: 28194570]


Sutherland HG, Griffiths LR. Genetics of Migraine: Insights into the Molecular Basis of Migraine Disorders. Headache. 2017 Apr:57(4):537-569. doi: 10.1111/head.13053. Epub 2017 Mar 8     [PubMed PMID: 28271496]


Viana M, Tronvik EA, Do TP, Zecca C, Hougaard A. Clinical features of visual migraine aura: a systematic review. The journal of headache and pain. 2019 May 30:20(1):64. doi: 10.1186/s10194-019-1008-x. Epub 2019 May 30     [PubMed PMID: 31146673]

Level 1 (high-level) evidence


Evans RW, Burch RC, Frishberg BM, Marmura MJ, Mechtler LL, Silberstein SD, Turner DP. Neuroimaging for Migraine: The American Headache Society Systematic Review and Evidence-Based Guideline. Headache. 2020 Feb:60(2):318-336. doi: 10.1111/head.13720. Epub 2019 Dec 31     [PubMed PMID: 31891197]

Level 1 (high-level) evidence


Hsu YC, Lin KC, Taiwan Headache Society TGSOTHS. Medical Treatment Guidelines for Acute Migraine Attacks. Acta neurologica Taiwanica. 2017 Jun 15:26(2):78-96     [PubMed PMID: 29250761]


Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul-Aug:55 Suppl 4():221-35. doi: 10.1111/head.12601. Epub 2015 Jul 14     [PubMed PMID: 26178694]

Level 1 (high-level) evidence


Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun:55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15     [PubMed PMID: 25877672]


Biglione B, Gitin A, Gorelick PB, Hennekens C. Aspirin in the Treatment and Prevention of Migraine Headaches: Possible Additional Clinical Options for Primary Healthcare Providers. The American journal of medicine. 2020 Apr:133(4):412-416. doi: 10.1016/j.amjmed.2019.10.023. Epub 2019 Nov 9     [PubMed PMID: 31712099]


Brandes JL, Kudrow D, Stark SR, O'Carroll CP, Adelman JU, O'Donnell FJ, Alexander WJ, Spruill SE, Barrett PS, Lener SE. Sumatriptan-naproxen for acute treatment of migraine: a randomized trial. JAMA. 2007 Apr 4:297(13):1443-54     [PubMed PMID: 17405970]

Level 1 (high-level) evidence


Dodick DW, Lipton RB, Ailani J, Lu K, Finnegan M, Trugman JM, Szegedi A. Ubrogepant for the Treatment of Migraine. The New England journal of medicine. 2019 Dec 5:381(23):2230-2241. doi: 10.1056/NEJMoa1813049. Epub     [PubMed PMID: 31800988]


Kuca B, Silberstein SD, Wietecha L, Berg PH, Dozier G, Lipton RB, COL MIG-301 Study Group. Lasmiditan is an effective acute treatment for migraine: A phase 3 randomized study. Neurology. 2018 Dec 11:91(24):e2222-e2232. doi: 10.1212/WNL.0000000000006641. Epub 2018 Nov 16     [PubMed PMID: 30446595]

Level 1 (high-level) evidence


Giamberardino MA, Affaitati G, Costantini R, Guglielmetti M, Martelletti P. Acute headache management in emergency department. A narrative review. Internal and emergency medicine. 2020 Jan:15(1):109-117. doi: 10.1007/s11739-019-02266-2. Epub 2020 Jan 1     [PubMed PMID: 31893348]

Level 3 (low-level) evidence


Mirbaha S, Delavar-Kasmaei H, Erfan E. Effectiveness of the Concurrent Intravenous Injection of Dexamethasone and Metoclopramide for Pain Management in Patients with Primary Headaches Presenting to Emergency Department. Advanced journal of emergency medicine. 2017 Fall:1(1):e6. doi: 10.22114/AJEM.v1i1.12. Epub 2017 Oct 12     [PubMed PMID: 31172058]


Chou DE, Shnayderman Yugrakh M, Winegarner D, Rowe V, Kuruvilla D, Schoenen J. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia : an international journal of headache. 2019 Jan:39(1):3-14. doi: 10.1177/0333102418811573. Epub 2018 Nov 17     [PubMed PMID: 30449151]

Level 1 (high-level) evidence


Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, Goadsby PJ. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. The journal of headache and pain. 2015:16():535. doi: 10.1186/s10194-015-0535-3. Epub 2015 Jun 3     [PubMed PMID: 26055242]

Level 3 (low-level) evidence


Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, Charles AC, Goadsby PJ, Lipton RB, Silberstein SD, Gelfand AA, Chiacchierini RP, Dodick DW. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia : an international journal of headache. 2018 May:38(6):1038-1048. doi: 10.1177/0333102418762525. Epub 2018 Mar 4     [PubMed PMID: 29504483]

Level 2 (mid-level) evidence


Rapoport AM, Bonner JH, Lin T, Harris D, Gruper Y, Ironi A, Cowan RP. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. The journal of headache and pain. 2019 Jul 22:20(1):83. doi: 10.1186/s10194-019-1033-9. Epub 2019 Jul 22     [PubMed PMID: 31331265]


Korucu O, Dagar S, Çorbacioglu ŞK, Emektar E, Cevik Y. The effectiveness of greater occipital nerve blockade in treating acute migraine-related headaches in emergency departments. Acta neurologica Scandinavica. 2018 Sep:138(3):212-218. doi: 10.1111/ane.12952. Epub 2018 May 10     [PubMed PMID: 29744871]


Crespi J, Bratbak D, Dodick DW, Matharu M, Jamtøy KA, Tronvik E. Pilot Study of Injection of OnabotulinumtoxinA Toward the Sphenopalatine Ganglion for the Treatment of Classical Trigeminal Neuralgia. Headache. 2019 Sep:59(8):1229-1239. doi: 10.1111/head.13608. Epub 2019 Jul 25     [PubMed PMID: 31342515]

Level 3 (low-level) evidence


Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24:78(17):1337-45. doi: 10.1212/WNL.0b013e3182535d20. Epub     [PubMed PMID: 22529202]

Level 2 (mid-level) evidence


Kahriman A, Zhu S. Migraine and Tension-Type Headache. Seminars in neurology. 2018 Dec:38(6):608-618. doi: 10.1055/s-0038-1673683. Epub 2018 Dec 6     [PubMed PMID: 30522135]


Holle-Lee D, Nägel S, Gaul C. [Therapy of migranes]. Der Nervenarzt. 2017 Aug:88(8):929-941. doi: 10.1007/s00115-017-0338-7. Epub     [PubMed PMID: 28497257]


Ruscheweyh R, Förderreuther S, Gaul C, Gendolla A, Holle-Lee D, Jürgens T, Neeb L, Straube A. [Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society]. Der Nervenarzt. 2018 Dec:89(12):1355-1364. doi: 10.1007/s00115-018-0534-0. Epub     [PubMed PMID: 29947936]


Zobdeh F, Eremenko II, Akan MA, Tarasov VV, Chubarev VN, Schiöth HB, Mwinyi J. Pharmacogenetics and Pain Treatment with a Focus on Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Antidepressants: A Systematic Review. Pharmaceutics. 2022 Jun 1:14(6):. doi: 10.3390/pharmaceutics14061190. Epub 2022 Jun 1     [PubMed PMID: 35745763]

Level 1 (high-level) evidence


Lipton RB, Munjal S, Brand-Schieber E, Tepper SJ, Dodick DW. Efficacy, Tolerability, and Safety of DFN-15 (Celecoxib Oral Solution, 25 mg/mL) in the Acute Treatment of Episodic Migraine: A Randomized, Double-Blind, Placebo-Controlled Study. Headache. 2020 Jan:60(1):58-70. doi: 10.1111/head.13663. Epub 2019 Oct 24     [PubMed PMID: 31647577]

Level 1 (high-level) evidence


Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan:55(1):3-20. doi: 10.1111/head.12499. Epub     [PubMed PMID: 25600718]


Derry CJ, Derry S, Moore RA. Sumatriptan (all routes of administration) for acute migraine attacks in adults - overview of Cochrane reviews. The Cochrane database of systematic reviews. 2014 May 28:2014(5):CD009108. doi: 10.1002/14651858.CD009108.pub2. Epub 2014 May 28     [PubMed PMID: 24865446]

Level 3 (low-level) evidence


Cady RK, Munjal S, Cady RJ, Manley HR, Brand-Schieber E. Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine. The journal of headache and pain. 2017 Dec:18(1):17. doi: 10.1186/s10194-016-0717-7. Epub 2017 Feb 7     [PubMed PMID: 28176235]

Level 1 (high-level) evidence


Havanka H, Dahlöf C, Pop PH, Diener HC, Winter P, Whitehouse H, Hassani H. Efficacy of naratriptan tablets in the acute treatment of migraine: a dose-ranging study. Naratriptan S2WB2004 Study Group. Clinical therapeutics. 2000 Aug:22(8):970-80     [PubMed PMID: 10972633]


Bird S, Derry S, Moore RA. Zolmitriptan for acute migraine attacks in adults. The Cochrane database of systematic reviews. 2014 May 21:2014(5):CD008616. doi: 10.1002/14651858.CD008616.pub2. Epub 2014 May 21     [PubMed PMID: 24848613]

Level 1 (high-level) evidence


Oldman AD, Smith LA, McQuay HJ, Moore AR. Pharmacological treatments for acute migraine: quantitative systematic review. Pain. 2002 Jun:97(3):247-257. doi: 10.1016/S0304-3959(02)00024-6. Epub     [PubMed PMID: 12044621]

Level 1 (high-level) evidence


. Eletriptan (relpax) for migraine. The Medical letter on drugs and therapeutics. 2003 Apr 28:45(1155):33-4     [PubMed PMID: 12719695]

Level 3 (low-level) evidence


Kelley NE, Tepper DE. Rescue therapy for acute migraine, part 2: neuroleptics, antihistamines, and others. Headache. 2012 Feb:52(2):292-306. doi: 10.1111/j.1526-4610.2011.02070.x. Epub     [PubMed PMID: 22309235]


Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. The New England journal of medicine. 2019 Jul 11:381(2):142-149. doi: 10.1056/NEJMoa1811090. Epub     [PubMed PMID: 31291516]


VanderPluym JH, Halker Singh RB, Urtecho M, Morrow AS, Nayfeh T, Torres Roldan VD, Farah MH, Hasan B, Saadi S, Shah S, Abd-Rabu R, Daraz L, Prokop LJ, Murad MH, Wang Z. Acute Treatments for Episodic Migraine in Adults: A Systematic Review and Meta-analysis. JAMA. 2021 Jun 15:325(23):2357-2369. doi: 10.1001/jama.2021.7939. Epub     [PubMed PMID: 34128998]

Level 1 (high-level) evidence


Capobianco DJ, Cheshire WP, Campbell JK. An overview of the diagnosis and pharmacologic treatment of migraine. Mayo Clinic proceedings. 1996 Nov:71(11):1055-66     [PubMed PMID: 8917290]

Level 3 (low-level) evidence


Ikeda K, Aoyagi J, Hanashiro S, Sawada M, Kyuzen M, Morioka H, Ebina J, Nagasawa J, Yanagihashi M, Ishikawa Y, Miura K, Murata K, Takazawa T, Kawabe K, Iwasaki Y. Preventive Treatment with Lomerizine Increases Cerebral Blood Flows during the Interictal Phase of Migraine. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2018 Apr:27(4):998-1002. doi: 10.1016/j.jstrokecerebrovasdis.2017.11.004. Epub 2017 Dec 6     [PubMed PMID: 29221971]


Ashina M, Goadsby PJ, Dodick DW, Tepper SJ, Xue F, Zhang F, Brennan F, Paiva da Silva Lima G. Assessment of Erenumab Safety and Efficacy in Patients With Migraine With and Without Aura: A Secondary Analysis of Randomized Clinical Trials. JAMA neurology. 2022 Feb 1:79(2):159-168. doi: 10.1001/jamaneurol.2021.4678. Epub     [PubMed PMID: 34928306]

Level 1 (high-level) evidence